Topical Low-Dose Naltrexone: An Emerging Therapy in topical LDN dermatology - Integrative Functional Medicine San Antonio Quincy
- John Kim
- Oct 6
- 4 min read
Introduction
Topical low-dose naltrexone (LDN) is gaining recognition as a promising therapy in dermatology. Investigated for its potential to relieve itching and reduce inflammation in chronic skin conditions, this treatment offers a novel approach for patients. Naltrexone itself is an opioid receptor antagonist. At low doses, typically formulated as a 1% cream or ointment for topical use, it modulates the body's natural opioid system and inflammatory responses. This article provides a methodical overview of topical LDN, exploring its mechanism, the clinical evidence supporting its use, its safety profile, and what the future may hold for this treatment.
Mechanism of Action
Understanding how topical LDN works begins with its effect on opioid receptors in the skin.
Opioid Receptor Blockade: When applied to the skin, LDN temporarily blocks specific opioid receptors. This brief blockade triggers a compensatory response in the body.
Upregulation of Endogenous Opioids: In response to the blockade, the body increases its production of endogenous opioids, such as endorphins. These natural pain-relievers and mood elevators play a key role in regulating sensation and inflammation.
Modulation of Inflammatory Pathways: LDN also influences immune system activity. It is believed to interact with Toll-like receptor 4 (TLR4), a key component of the innate immune system. By modulating this pathway, LDN can help reduce the production of inflammatory cytokines, which are molecules that drive inflammation in skin conditions like psoriasis and atopic dermatitis.
This localized action allows topical LDN to target skin-specific symptoms with minimal systemic absorption, offering a focused therapeutic effect.
Clinical Evidence for Efficacy
While still an emerging area of research, the existing clinical evidence for topical LDN is encouraging, particularly for conditions characterized by chronic itch (pruritus).
Pruritus Relief: The most significant findings relate to its antipruritic effects. A randomized, placebo-controlled trial involving patients with chronic pruritic conditions found that a 1% naltrexone cream provided substantial itch relief for more than 70% of participants. The onset of action was notably rapid, averaging around 46 minutes.
Histological Findings: Supporting these clinical results, skin biopsies from patients who experienced improvement showed an increase in the expression of μ-opioid receptors in the epidermis. This finding provides a biological correlation for the observed symptom relief.
Psoriasis Model: In vitro studies using a 1% naltrexone cream in a psoriasis model demonstrated a significant downregulation of cellular proliferation markers and inflammatory cytokines. This suggests that its benefits may extend beyond pruritus to other inflammatory skin diseases.
Systematic reviews confirm that while the body of evidence is composed of smaller studies and case reports, the results consistently point toward rapid and meaningful symptom improvement, especially for itch.
Safety and Tolerability Profile
For patients and clinicians considering a new therapy, safety is a primary concern. Topical LDN has demonstrated a favorable safety profile in clinical studies.
Minimal Side Effects: Unlike systemic (oral) naltrexone, which can sometimes cause side effects like transient insomnia, topical formulations are associated with very few adverse events. The local application minimizes systemic absorption, thereby reducing the risk of widespread side effects.
Good Tolerability: Patients in clinical trials have generally tolerated the cream well, with no significant adverse reactions reported in the major studies conducted to date.
This strong safety profile makes topical LDN an appealing option, particularly for patients who have not responded to or cannot tolerate other conventional treatments.
Limitations and Future Directions
Navigating the path to widespread clinical adoption requires addressing current limitations and pursuing further research. Experiencing a new treatment option can be a hopeful step, but it is important to understand the current state of the evidence.
The primary limitation is that the existing evidence comes from relatively small studies and case series. To establish topical LDN as a standard of care, larger and more robust randomized controlled trials are necessary.
Future research should focus on:
Defining Optimal Dosing: Establishing the most effective concentration and application frequency for various skin conditions.
Long-Term Safety: Evaluating the safety and tolerability of topical LDN over extended periods of use.
Broader Efficacy: Investigating its effectiveness across a wider range of dermatologic diseases, such as lichen planus, Hailey-Hailey disease, and other inflammatory dermatoses.
Conclusion
Topical low-dose naltrexone cream represents a supportive and innovative therapeutic option for managing challenging symptoms in dermatology, most notably chronic pruritus. Its unique mechanism, which leverages the body’s own regulatory systems, combined with a strong safety profile, makes it a promising avenue for patients seeking relief. While the current evidence is encouraging, the medical community looks forward to larger-scale studies to fully define its role and unlock its full potential in clinical practice. As always, patients should consult their healthcare provider to determine if this personalized health solution is appropriate for their health journey.
At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.
References
Bigliardi, P. L., Stammer, H., Jost, G., et al. (2007). Treatment of pruritus with topically applied opiate receptor antagonist. Journal of the American Academy of Dermatology, 56(6), 979-988.
Ekelem, C., Juhasz, M., Khera, P., & Mesinkovska, N. A. (2019). Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: A systematic review. JAMA Dermatology, 155(2), 229-236.
Zhou, M. H., Elston, D. M., Morrison, B. W., & Lipner, S. R. (2025). Low-dose naltrexone for treatment of dermatologic conditions: A clinical review. Journal of the American Academy of Dermatology, S0190-9622(25)02812-9.
Ip, K., Song, G., Banov, D., Bassani, A. S., & Valdez, B. C. (2020). In vitro evaluation of naltrexone HCl 1% topical cream in XemaTop™ for psoriasis. Archives of Dermatological Research, 312(2), 145-154.
Dodou, K., Armstrong, A., Kelly, I., et al. (2015). Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay. Pharmaceutical Development and Technology, 20(6), 694-701.
Sikora, M., Rakowska, A., Olszewska, M., & Rudnicka, L. (2019). The use of naltrexone in dermatology. Current evidence and future directions. Current Drug Targets, 20(10), 1058-1067.
Comments